Polyrizon

Company Overview

Snapshot

Founded in March 2020 by Tomer Izraeli, Polyrizon operates with 1–10 employees. The company has raised a total of $27.03 million across 9 funding rounds and went public on NASDAQ in October 2024.

Business overview

Polyrizon is a biotech company specializing in the development and commercialization of innovative intranasal products within the Health Tech & Life Sciences sector. Its core technologies include the Capture & Contain (C&C) platform, a natural 3D polymeric network designed to create a physical barrier against airborne contaminants like allergens, viruses, and molds, and the Trap & Target (T&T) platform, a delivery technology for highly effective targeted administration of medicines to mucosal tissue. The company serves markets focused on pharmaceutical and medical biotechnology, particularly in drug delivery, and aims to protect the human body from various airborne threats and improve therapeutic effects for different molecules.

Strategic signal

Polyrizon is actively advancing its product pipeline and intellectual property, as evidenced by the recent U.S. patent publication for its mucoadhesive drug delivery platform in June 2026. This patent expansion strengthens the company's competitive position in intranasal drug delivery and signals a continued focus on innovation and market protection for its proprietary technologies.

Company Intelligence Q&A

What was a significant financial milestone for Polyrizon in late 2024?

In October 2024, Polyrizon completed an Initial Public Offering, listing on the Nasdaq Capital Market under the ticker “PLRZ”.

What recent progress has Polyrizon made in its clinical development for NASARIX™?

In June 2026, Polyrizon secured three U.S. clinical sites for its NASARIX™ Allergy Blocker clinical trial, advancing towards human clinical trials. This follows the securing of the first U.S. clinical site in May 2026.

What recent intellectual property development did Polyrizon announce?

In June 2026, Polyrizon received notice of U.S. patent publication for its mucoadhesive drug delivery platform, further expanding its intellectual property in intranasal drug delivery.

What strategic move did Polyrizon announce in March 2026?

In March 2026, Polyrizon announced its intention to acquire up to a 20% stake in Colugo, a developer of advanced eVTOL drones for defense and urban air mobility applications, indicating a potential diversification strategy.

What preclinical results did Polyrizon announce regarding its PL-14 Allergy Blocker?

In October 2025, Polyrizon announced positive preclinical results for its PL-14 Allergy Blocker, demonstrating encouraging allergen-blocking efficacy. This was followed by successful intranasal delivery studies reported in September 2025 and July 2025.